|
|
|
IBCSG 25-02 / BIG 3-02 (TEXT)
A phase III trial evaluating the role of exemestane plus GnRH analogue as adjuvant therapy for premenopausal women with endocrine responsive breast cancer Tamoxifen and Exemestane Trial (TEXT)
DESIGN
TEXT-Bone Substudy
The TEXT-Bone Substudy investigates serial bone markers for bone remodeling, serial growth factors, and bone mineral density for TEXT patients in selected centers. |
|
Study ChairsBIG: Dr. Olivia Pagani - Mendrisio, Switzerland
US Intergroup: Dr. Barbara Walley - Calgary, CanadaStatisticianDr. Meredith ReganTrial CoordinatorsKarolyn Scott, Jocelyn Swick, Chris Rickard, Tara Scolese
IBCSG Data Management Center/FSTRF 4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 836 6097
Email: ibcsg24-26_STP@fstrf.orgDate of ActivationAugust 4, 2003Targeted Accrual1845 patients
 Pathology
News
27.08.2010:
Activation of IBCSG Trial 38-10/BIG 3-07/TROG 07.01
19.08.2010:
A few impressions from our audits
09.08.2010:
Latest SOLE flash
All News
|
|